Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Ttp399
1. Ttp399
2. Cadisegliatin [usan]
3. 98s8sh8unf
4. Nn9108
5. Nnc 80-3315
6. Ttp-00223399
7. 859525-02-3
8. Nnc 0080-0000-3315
9. Unii-98s8sh8unf
10. Schembl999940
11. Schembl999941
12. Schembl2648148
13. Schembl21516045
14. Ttp-399
15. Glxc-25387
16. Who 12146
17. Zinc115001082
18. Zinc149397570
19. Nn-9108
20. Hy-147254
21. Cs-0542308
22. {2-[3-cyclohexyl-3-(cis-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic Acid
23. {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic Acid
24. 2-((2-(3-cyclohexyl-3-((1r,4r)-4-propoxycyclohexyl)ureido)thiazol-5-yl)thio)acetic Acid
25. Acetic Acid, 2-((2-(((cyclohexyl(trans-4-propoxycyclohexyl)amino)carbonyl)amino)-5-thiazolyl)thio)-
| Molecular Weight | 455.6 g/mol |
|---|---|
| Molecular Formula | C21H33N3O4S2 |
| XLogP3 | 4.8 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 9 |
| Exact Mass | 455.19124889 g/mol |
| Monoisotopic Mass | 455.19124889 g/mol |
| Topological Polar Surface Area | 145 Ų |
| Heavy Atom Count | 30 |
| Formal Charge | 0 |
| Complexity | 554 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
Details:
Th proceeds will fund ongoing CATT1 Phase 3 and continued development of TTP399 (cadisegliatin), a novel, first-in-class oral adjunctive therapy to insulin being investigated for type 1 diabetes.
Lead Product(s): Cadisegliatin,Inapplicable
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Samsara BioCapital
Deal Size: $80.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement September 02, 2025
Lead Product(s) : Cadisegliatin,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Samsara BioCapital
Deal Size : $80.0 million
Deal Type : Private Placement
vTv Therapeutics Announces $80 Million Private Placement
Details : Th proceeds will fund ongoing CATT1 Phase 3 and continued development of TTP399 (cadisegliatin), a novel, first-in-class oral adjunctive therapy to insulin being investigated for type 1 diabetes.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 02, 2025
Details:
TTP399 (cadisegliatin) is a novel, oral small molecule, liver selective glucokinase activator being investigated as first-in-class oral adjunctive treatment to insulin for type 1 diabetes (T1D).
Lead Product(s): Cadisegliatin,Inapplicable
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 15, 2025
Lead Product(s) : Cadisegliatin,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
vTv Resumes Screening in Phase 3 CATT1 Trial for Liver-Targeted Cadisegliatin
Details : TTP399 (cadisegliatin) is a novel, oral small molecule, liver selective glucokinase activator being investigated as first-in-class oral adjunctive treatment to insulin for type 1 diabetes (T1D).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 15, 2025
Details:
TTP399 (cadisegliatin) is a novel, oral small molecule, liver selective glucokinase activator being investigated as first-in-class oral adjunctive treatment to insulin for type 1 diabetes (T1D).
Lead Product(s): Cadisegliatin,Inapplicable
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 17, 2025
Lead Product(s) : Cadisegliatin,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
vTv Therapeutics Says FDA Lifts Clinical Hold on Cadisegliatin Program for Diabetes
Details : TTP399 (cadisegliatin) is a novel, oral small molecule, liver selective glucokinase activator being investigated as first-in-class oral adjunctive treatment to insulin for type 1 diabetes (T1D).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 17, 2025
Details:
TTP399 (cadisegliatin) is an investigational liver-selective glucokinase activator that has been studied in healthy volunteers and in patients with type 1 and type 2 diabetes.
Lead Product(s): Cadisegliatin,Inapplicable
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 26, 2024
Lead Product(s) : Cadisegliatin,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
vTv Therapeutics Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold
Details : TTP399 (cadisegliatin) is an investigational liver-selective glucokinase activator that has been studied in healthy volunteers and in patients with type 1 and type 2 diabetes.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 26, 2024
Details:
TTP399 (cadisegliatin) is a novel, oral small molecule, liver-selective glucokinase activator with first-in-class potential as an adjunct treatment for type 1 diabetes.
Lead Product(s): Cadisegliatin,Inapplicable
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 24, 2024
Lead Product(s) : Cadisegliatin,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
vTv Announces Screening of First Patient in CATT1 Trial for Type 1 Diabetes
Details : TTP399 (cadisegliatin) is a novel, oral small molecule, liver-selective glucokinase activator with first-in-class potential as an adjunct treatment for type 1 diabetes.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 24, 2024
Details:
Cadisegliatin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diabetes Mellitus, Type 1.
Lead Product(s): Cadisegliatin,Inapplicable
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 27, 2024
Lead Product(s) : Cadisegliatin,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes
Details : Cadisegliatin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diabetes Mellitus, Type 1.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 27, 2024
Details:
TTP399 (cadisegliatin) is an investigational liver-selective glucokinase activator that has been studied in healthy volunteers and in patients with type 1 and type 2 diabetes.
Lead Product(s): Cadisegliatin,Inapplicable
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 04, 2024
Lead Product(s) : Cadisegliatin,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
vTv Submits FDA Application for First Phase 3 Study of Cadisegliatin in Type 1 Diabetes
Details : TTP399 (cadisegliatin) is an investigational liver-selective glucokinase activator that has been studied in healthy volunteers and in patients with type 1 and type 2 diabetes.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 04, 2024
Details:
vTv will utilize the net proceeds to finance the initial Phase 3 trial of its primary product candidate, TTP399 (cadisegliatin), a glucokinase activator intended for treating type 1 diabetes.
Lead Product(s): Cadisegliatin,Inapplicable
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Samsara BioCapital
Deal Size: $51.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement February 28, 2024
Lead Product(s) : Cadisegliatin,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Samsara BioCapital
Deal Size : $51.0 million
Deal Type : Private Placement
vTv Therapeutics Announces $51 Million Private Placement
Details : vTv will utilize the net proceeds to finance the initial Phase 3 trial of its primary product candidate, TTP399 (cadisegliatin), a glucokinase activator intended for treating type 1 diabetes.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
February 28, 2024
Details:
The proceeds will provide vTv with important financial support for preparing the launch of the TTP399 (cadisegliatin), a potential adjunctive therapy to insulin, phase 3 program in the treatment of type 1 diabetes.
Lead Product(s): Cadisegliatin,Inapplicable
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Reneo Pharmaceuticals
Deal Size: $4.4 million Upfront Cash: Undisclosed
Deal Type: Agreement November 01, 2023
Lead Product(s) : Cadisegliatin,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Reneo Pharmaceuticals
Deal Size : $4.4 million
Deal Type : Agreement
vTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 Million
Details : The proceeds will provide vTv with important financial support for preparing the launch of the TTP399 (cadisegliatin), a potential adjunctive therapy to insulin, phase 3 program in the treatment of type 1 diabetes.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
November 01, 2023
Details:
In addition to the investment, the agreements set forth the terms under which vTv will leverage the CinRx team’s industry experience to collaborate on the oversight of the clinical trials for pharmaceutical products that contain TTP399.
Lead Product(s): Cadisegliatin,Inapplicable
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: CinRx Pharma
Deal Size: $10.0 million Upfront Cash: $6.0 million
Deal Type: Agreement July 25, 2022
Lead Product(s) : Cadisegliatin,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : CinRx Pharma
Deal Size : $10.0 million
Deal Type : Agreement
vTv Therapeutics Announces Investment by CinRx Pharma
Details : In addition to the investment, the agreements set forth the terms under which vTv will leverage the CinRx team’s industry experience to collaborate on the oversight of the clinical trials for pharmaceutical products that contain TTP399.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $6.0 million
July 25, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
21
PharmaCompass offers a list of Cadisegliatin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Cadisegliatin manufacturer or Cadisegliatin supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Cadisegliatin manufacturer or Cadisegliatin supplier.
PharmaCompass also assists you with knowing the Cadisegliatin API Price utilized in the formulation of products. Cadisegliatin API Price is not always fixed or binding as the Cadisegliatin Price is obtained through a variety of data sources. The Cadisegliatin Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Cadisegliatin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Cadisegliatin, including repackagers and relabelers. The FDA regulates Cadisegliatin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Cadisegliatin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Cadisegliatin supplier is an individual or a company that provides Cadisegliatin active pharmaceutical ingredient (API) or Cadisegliatin finished formulations upon request. The Cadisegliatin suppliers may include Cadisegliatin API manufacturers, exporters, distributors and traders.
Cadisegliatin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Cadisegliatin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Cadisegliatin GMP manufacturer or Cadisegliatin GMP API supplier for your needs.
A Cadisegliatin CoA (Certificate of Analysis) is a formal document that attests to Cadisegliatin's compliance with Cadisegliatin specifications and serves as a tool for batch-level quality control.
Cadisegliatin CoA mostly includes findings from lab analyses of a specific batch. For each Cadisegliatin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Cadisegliatin may be tested according to a variety of international standards, such as European Pharmacopoeia (Cadisegliatin EP), Cadisegliatin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Cadisegliatin USP).
